The case of cerivastatin. What lesson for the clinical practice?;Cerivastatina. Quale lezione per la pratica clinica?

Recenti Progressi in Medicina

Volumn 92, Issue 11, 2001, Pages 641-643

  Cartabellotta, Antonino ^a,b  

^a GIMBE   (Italy)

^b Gruppo Ital Per Med Basata S   (Italy)

Author keywords

Adverse drug reactions; Appropriateness; Cerivastatin; Drug prescription; Evidence based pharmacotherapy; Post marketing surveillance

Indexed keywords

ATORVASTATIN; CALCIUM ANTAGONIST; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; SHORT SURVEY;

HUMANS; PRESCRIPTIONS, DRUG; PYRIDINES;

EID: 0035213465     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (24)

1. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999; 282: 1371-7.
2. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999; 282: 786-90.
3. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med 2000;132:715-22.
4. Ministero della Sanità. L'uso dei farmaci in Italia. Rapporto Nazionale 2000.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
6. Kaplan NM. Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II. Arch Intern Med 2001; 161: 511-2.
7. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-43.
8. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet 2000; 356: 1339-43.
9. Jick H, Garcia Rodriguez LA, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998; 352: 1767-70.
10. Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000; 356: 1505-11.
11. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions. Current perspectives and future needs. JAMA. 1999; 281: 824-9.
12. Edzard Ernst, Max H Pittler. Assessment of therapeutic safety in systematic reviews: literature review. BMJ 2001; 323: 546.
13. Cohen JS. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 2001; 161: 957-64.
14. Hutchinson TA. Bayesian assessment of adverse drug reactions. CMAJ 2000; 163: 1463-4.
15. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed". BMJ 2000; 320: 503-6.
16. Ross SD. Drug-related adverse events: a readers' guide to assessing literature reviews and meta-analyses. Arch Intern Med 2001; 161: 1041-6.
17. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA 1999; 281: 841-4.
18. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other ncnsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158: 33-9.
19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: metaanalysis. BMJ 2000; 321: 1183-7.
20. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. BMJ 1998; 316: 1303-9.
21. Lubsen J, Tijssen JG. Large trials with simple protocols: indications and contraindications. Control Clin Trials 1989; 10(4 suppl): 151S-60S.
22. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311: 1356-9.
23. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-8.
24. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.